Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H39N3O4.H2O4S |
| Molecular Weight | 555.684 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.NC(=O)C1=CC=CC(=C1)[C@@H]2C[C@@H]3CC[C@H](C2)N3CCN(CC4CCCCC4)C(=O)[C@@H](O)CO
InChI
InChIKey=QNFFAKFVKCGLPK-WTKDUOFSSA-N
InChI=1S/C26H39N3O4.H2O4S/c27-25(32)20-8-4-7-19(13-20)21-14-22-9-10-23(15-21)29(22)12-11-28(26(33)24(31)17-30)16-18-5-2-1-3-6-18;1-5(2,3)4/h4,7-8,13,18,21-24,30-31H,1-3,5-6,9-12,14-17H2,(H2,27,32);(H2,1,2,3,4)/t21-,22+,23-,24-;/m0./s1
Axelopran (previously known as TD-1211), a peripherally selective, multivalent µ-opioid receptor antagonist that is under development by Theravance Biopharma. This drug participated in phase II clinical trials in subjects with opioid-induced constipation. The most common adverse events were abdominal pain, nausea, and diarrhea. There were no indications of opioid withdrawal effects or reductions in opioid analgesia in patients treated with axelopran.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Clinical Overview and Considerations for the Management of Opioid-induced Constipation in Patients With Chronic Noncancer Pain. | 2019-02 |
|
| Discovery of N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenol and -phenyl carboxamide series of μ-opioid receptor antagonists. | 2017-07-01 |
|
| Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain. | 2016-03 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01401985
Capsules once daily
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C681
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CHEMBL3137313
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
PRIMARY | |||
|
300000044464
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
PRIMARY | |||
|
DBSALT002121
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
PRIMARY | |||
|
BC-62
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
PRIMARY | |||
|
949904-50-1
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
PRIMARY | |||
|
1050202-71-5
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
C142943
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
PRIMARY | |||
|
8OJM0A31U9
Created by
admin on Mon Mar 31 22:12:52 GMT 2025 , Edited by admin on Mon Mar 31 22:12:52 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD